Printer Friendly


Lipid Sciences, Inc. (Nasdaq:LIPD), Pleasanton, Calif., has announced that the latest results of both in vivo and in vitro studies supporting the company's Viral Immunotherapy Platform have been presented at the Keystone Symposium, HIV Vaccines: Current Challenges and Future Prospects. The Keystone Symposium is a non-profit organization directed and supported by the scientific community. This HIV Vaccine Development meeting has gained a reputation as an important forum for presenting new data in the area of HIV research and is attended by recognized experts in the field worldwide. This meeting was held in Banff, Alberta, Canada.

On April 11, 2005 a poster and presentation entitled "Delipidated Retroviruses as Potential Autologous Therapeutic Vaccines - A Pilot Experiment" was given by Moiz Kitabwalla, Ph.D., manager of Viral Programs at Lipid Sciences. This study was designed to demonstrate whether or not there was a measurable immune system response to delipidated Simian Immunodeficiency Virus ("SIV") in SIV-infected monkeys, a widely-accepted primate model for viral diseases like HIV. This preliminary study was able to demonstrate that the SIV viral antigen delipidated by Lipid Sciences' proprietary delipidation process was efficiently recognized by the animals' immune system and has resulted in a measurable improvement in the conventional indicators of overall health in these study animals. These results included a viral load reduction by 90+%, weight gain, and extended post infection survival. The ability to use small amounts of a patient's autologous circulating viral antigen to generate a virus-specific immune response could potentially lead to the control of viral replication and provide a unique approach to the development of an effective treatment for chronic HIV infection. This study was conducted under the direction of Aftab A. Ansari, Ph.D., professor, Department of Pathology and Laboratory Medicine, Emory University. Dr. Ansari is a member of Lipid Sciences' Viral Advisory Board.

S. Lewis Meyer, Ph.D. president and CEO of Lipid Sciences commented, "With these very positive results as a backdrop, by mid-2005 we plan to launch a pre-clinical safety and effectiveness study in a statistically significant group of SIV infected non-human primates. The intent of this study will be to gather sufficient information to begin our dialogue with the Food and Drug Administration about a human clinical trial for the treatment of HIV-infected patients--clearly a major milestone for Lipid Sciences."

Also on display at the Symposium was our poster entitled, "Solvent-treated Retroviruses as Novel Vaccines - A Study in Characterizing Delipidated Retroviruses." These in vitro experiments demonstrated that our proprietary delipidation process removed the majority of all lipids from the virus. This lipid removal was confirmed by electrospray ionization mass spectrometry. The delipidated viruses appear to represent a promising approach to the development of a therapy to treat HIV infected patients. This study was conducted under the direction of Dr. James E.K. Hildreth, M.D., Ph.D., professor of Pharmacology and Molecular Sciences, and of Pathology at Johns Hopkins University School of Medicine. Dr. Hildreth is a member of Lipid Sciences' Viral Advisory Board.

Lipid Sciences, Inc. is a development-stage biotechnology company engaged in the research and development of products and processes to treat major medical indications in which lipids, or fat components, play a key role. The company's technologies are based on a unique patented process, known as delipidation, which removes lipids from targeted proteins. The company's HDL Therapy Platform is aimed at developing treatments for the reversal of atherosclerosis, a systemic disease of the blood vessels caused by the build-up of cholesterol-filled plaques in the vascular system and, most critically, in the coronary arteries. If left untreated, these plaques are highly vulnerable to rupture and to blood clot formation, which can result in a fatal myocardial infarction (heart attack). Regression of such plaques may have a major impact on reducing the risk of acute coronary events. The company's Viral Immunotherapy Platform is focused on the removal of the lipid envelope from certain viruses and other lipid-containing infectious agents by application of its delipidation technology. The company believes that removing the infectious agent's protective lipid envelope exposes otherwise hidden viral proteins, thereby stimulating the body's immune system to elicit an enhanced response to the infectious agent. Conditions that could potentially be impacted by this technology include HIV, Hepatitis B and Hepatitis C, West Nile, SARS, and influenza.

For more information, visit or call 212/253-8881.
COPYRIGHT 2005 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Biotech
Geographic Code:1USA
Date:Jun 1, 2005

Related Articles
Lipid takes a stand against alcohol.
...from the 7th Conferences on Retroviruses and Opportunistic Infections.
... from the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy.
Effect of black tea on the fasting concentrations of chylomicrons and chylomicron remnants in humans. (Original Research).
Retroviruses conference clinical news: interview with Cal Cohen, M.D.
Reduce caloric levels in gel systems.
OSU scientists unlock vitamin C's ability to neutralize body toxins.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters